Why We Itch: An Evolutionary View of Pruritus ➜ DOI: 10.1016/j.neuron.2025.12.039 This thought-provoking review explores pruritus through an evolutionary and neurobiological lens, linking normal itch to survival mechanisms such as parasite defense, grooming, and environmental vigilance. It highlights how these protective pathways can become maladaptive, contributing to chronic pathological itch in conditions such as atopic dermatitis and prurigo. The authors integrate neuroscience, immunology, and behavior to show how itch circuits are shaped by evolutionary pressures yet amplified by modern environments. This perspective helps explain why chronic itch is so persistent and difficult to treat. A stimulating upstream contribution for clinicians and researchers seeking a broader conceptual framework for pruritus beyond skin inflammation alone.
Taurine, Oxygen Sensing and AD: A New Predisposing Metabolic Pathway? ➜ DOI: 10.2340/actadv.v106.43770 This experimental study identifies ADO (cysteamine dioxygenase) as a novel genetic–metabolic contributor to atopic dermatitis. Risk variants and lesional skin show increased ADO expression, linked to Th2 cytokines, oxidative stress, and barrier dysfunction. Functional models in keratinocytes and zebrafish support a role in epidermal homeostasis and inflammation. Importantly, this pathway deserves particular investigation in FLG–non-mutated AD populations, especially in Sub-Saharan African ancestry groups where FLG loss-of-function mutations are less prevalent. An intriguing but early signal pointing toward metabolism-based therapeutic strategies and broader genetic diversity in AD.
When Cytokines Loosen the Barrier: Protease Activation in AD Skin Model ➜ DOI: 10.1111/1346-8138.70160 An in-vitro study shows that an AD-relevant cytokine milieu enhances epidermal trypsin-like serine protease activity. This mechanism may contribute to barrier fragilization, particularly in non-FLG–mutated atopic dermatitis. Topical corticosteroids, tacrolimus, and JAK inhibition suppressed this cytokine-driven protease activation. However, the findings rely solely on keratinocyte models without clinical or in-vivo confirmation. A stimulating but still preliminary link between Th2 inflammation and protease-mediated barrier damage.
Can AI Decode the Gut–Skin Axis in AD? ➜ DOI: 10.3389/fimmu.2025.1670993 This prospective study introduces ATOMIC, a graph-attention deep learning model predicting atopic dermatitis from gut microbiome data. The model integrates microbial co-expression networks and genomic features, identifying candidate taxa linked to immune pathways. Performance is promising but based on a small adult cohort and genus-level 16S data. Importantly, predictive accuracy does not establish causality or therapeutic relevance. A stimulating step toward microbiome-guided stratification in AD—methodologically innovative, clinically exploratory.
From Itch to Oncology: What Oclacitinib Teaches Us About JAK1 ➜ DOI: 10.1038/s41598-026-40066-9 Oclacitinib, a JAK1 inhibitor used since 2014 in canine atopic dermatitis (CAD), shows antitumor effects in canine lymphoma models dependent on JAK1/STAT5 signaling. Tumor sensitivity correlated with STAT5 phosphorylation and c-Myc downregulation. Although full cytotoxicity required higher concentrations, growth inhibition occurred at clinically relevant levels. These findings are reassuring in the context of chronic JAK inhibition and malignancy concerns. A compelling example of comparative dermatology linking long-term CAD therapy to broader immunologic and oncologic insights which may pertain to human AD.
